

解説演題一覧

消化器がん1 (肝胆膵)

解説：今岡 大 先生 (国立がん研究センター東病院)

演題番号	演 題	演 者
LBA50	IMbrave152/SKYSCRAPER-14: a phase 3 study of first-line tiragolumab (tira) + atezolizumab (atezo) + bevacizumab (bev) vs placebo (pbo) + atezo + bev for patients (pts) with untreated locally advanced or metastatic hepatocellular carcinoma (HCC)	Richard Finn
LBA51	IKF-035/ABC-HCC: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoembolization (TACE) in intermediate-stage HepatoCellular Carcinoma	Peter Galle
LBA84	Efficacy and safety of GFH375 monotherapy in previously treated advanced KRAS G12D-mutant pancreatic ductal adenocarcinoma (PDAC)	Aiping Zhou
9160	Preliminary Phase 1 Results of INCB161734, A Novel Oral KRAS G12D Inhibitor, In Patients With Advanced or Metastatic Solid Tumors	Jayesh Desai
22150	HRS-4642 combined with gemcitabine and nab-paclitaxel in KRAS-G12D mutant advanced pancreatic cancer: A phase Ib/II study	Liwei Wang

消化器がん2 (消化管)

解説：安藤 孝将 先生 (富山大学)

演題番号	演 題	演 者
LBA29	Nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): new results from CheckMate 8HW	Sara Lonardi
LBA10	Bemarituzumab (BEMA) plus chemotherapy for advanced or metastatic FGFR2b-overexpressing gastric or gastroesophageal junction cancer (G/GEJC): FORTITUDE-101 phase III study results	Sun Young Rha
20940	SKYSCRAPER-07: A phase III, randomised study of atezolizumab (atezo) with or without tiragolumab (tira) in patients (pts) with unresectable esophageal squamous cell carcinoma (ESCC) that has not progressed following definitive concurrent chemoradiotherapy (dCRT)	Ian Chau

乳がん

解説：齋藤 亜由美 先生 (国立がん研究センター中央病院)・酒井 瞳 先生 (昭和医科大学)

演題番号	演 題	演 者
LBA18	Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): additional analyses of DESTINY-Breast09 in key subgroups of interest	Sibylle Loibl
LBA1	Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2-positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05	Charles Geyer
2910	DESTINY-Breast11: neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC)	Nadia Harbeck
LBA16	Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2- aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the Phase III evERA BC trial	Erica Mayer
LBA20	Primary Results From ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Chemotherapy (Chemo) in Patients (pts) With Previously Untreated Advanced Triple-Negative Breast Cancer (TNBC) Who Are Unable to Receive PD-(L)1 Inhibitors (PD-[L]1i)	Javier Cortés
LBA21	First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial	Rebecca A. Dent

婦人科がん

解説：山本 香澄 先生 (兵庫県立がんセンター)

演題番号	演 題	演 者
10640	ICON8B: GCIG Phase III Randomised Trial Comparing First-line Weekly Dose-Dense Chemotherapy + Bevacizumab To Three-Weekly Chemotherapy + Bevacizumab In High-Risk Stage III-IV Epithelial Ovarian Cancer (EOC): Final Overall Survival (OS) Analysis	Andrew R. Clamp
LBA3	Pembrolizumab vs Placebo Plus Weekly Paclitaxel ± Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer: Results from the Randomized Double-Blind Phase 3 ENGOT-ov65/KEYNOTE-B96 Study	Nicoletta Colombo
LBA44	Durvalumab + paclitaxel/carboplatin + bevacizumab followed by durvalumab, bevacizumab + olaparib maintenance in patients with newly diagnosed non-tBRCA-mutated advanced ovarian cancer: final overall survival from DUO-O/ENGOT-ov46/GOG-3025	Carol Aghajanian

泌尿器がん

解説：加藤 大悟 先生 (大阪大学)

演題番号	演 題	演 者
LBA6	Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAAddition)	Scott T. Tagawa
LBA2	Perioperative (perip) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase III KEYNOTE-905 study	Christof Vulsteke
LBA96	First-line pembrolizumab-based regimens for advanced clear cell renal cell carcinoma: KEYMAKER-U03 substudy 03A	Cristina Suarez Rodriguez

その他 (頭頸部がん)

解説：山崎 知子 先生 (埼玉医科大学)

演題番号	演 題	演 者
LBA49	Primary endpoint analysis of the BD4QoL study, a multicenter randomized trial for monitoring quality of life by intelligent tools in head and neck cancer survivors after curative treatment	Stefano Cavalieri
13220	A phase III randomized trial of prophylactic radiation with 2-step40 versus SIB56 IMRT techniques for locally advanced squamous cell carcinoma of the head and neck (JCOG1912, NEW BRIDGE)	Takeshi Kodaira

その他 (肉腫など)

解説：仲野 兼司 先生 (がん研究会有明病院)

演題番号	演 題	演 者
LBA54	SARS-CoV-2 mRNA vaccines sensitize tumors to immune checkpoint blockade	Adam Grippin
LBA97	Legubicin versus doxorubicin (DOX) in patients (pts) with advanced soft tissue sarcoma (STS): Results of randomized, phase II/III study	Zan Shen
26840	ARTEMIS-002: A Phase 2 Study of HS-20093 in Patients with Relapsed or Refractory Sarcomas	Lu Xie

肺がん

解説：新野 祐樹 先生 (国立がん研究センター中央病院)・古屋 直樹 先生 (聖マリアンナ医科大学)

演題番号	演 題	演 者
LBA74	Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: Beamion LUNG 1	Sanjay Popat
LBA75	Sevabertinib (BAY 2927088) in advanced HER2-mutant non-small cell lung cancer (NSCLC): Results from the SOHO-01 study	Xiuning Le
LBA5	Sacituzumab tirumotecan (sac-TMT) vs platinum-based chemotherapy in EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) following progression on EGFR-TKIs: results from the randomized, multi-center phase III OptiTROP-Lung04 study	Li Zhang
LBA4	Phase III study of ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer (HARMONI-6)	Shun Lu
27570	Tarlatamab with first-line chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC): DeLLphi-303 study	Martin Wermke